Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Cash & Equivalents: 2019-2024

Historic Cash & Equivalents for Allogene Therapeutics (ALLO) over the last 6 years, with Dec 2024 value amounting to $75.2 million.

  • Allogene Therapeutics' Cash & Equivalents fell 26.20% to $37.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.8 million, marking a year-over-year decrease of 26.20%. This contributed to the annual value of $75.2 million for FY2024, which is 9.54% down from last year.
  • Latest data reveals that Allogene Therapeutics reported Cash & Equivalents of $75.2 million as of FY2024, which was down 9.54% from $83.2 million recorded in FY2023.
  • Allogene Therapeutics' 5-year Cash & Equivalents high stood at $183.4 million for FY2020, and its period low was $61.9 million during FY2022.
  • Moreover, its 3-year median value for Cash & Equivalents was $75.2 million (2024), whereas its average is $73.4 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first plummeted by 64.28% in 2022, then skyrocketed by 34.33% in 2023.
  • Allogene Therapeutics' Cash & Equivalents (Yearly) stood at $183.4 million in 2020, then decreased by 5.47% to $173.3 million in 2021, then plummeted by 64.28% to $61.9 million in 2022, then spiked by 34.33% to $83.2 million in 2023, then decreased by 9.54% to $75.2 million in 2024.